ArticleBMC medical imaging2026
Extracellular volume fraction derived from spectral CT for liver function reserve evaluation and complication prediction in clinically stable liver cirrhosis.
Article in BMC medical imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo investigate the value of spectral CT-derived extracellular volume fraction (fECV) in assessing liver functional reserve and predicting cirrhosis-related complications in clinically stable cirrhotic patients. MATERIALS AND
methodsThis retrospective study enrolled clinically stable patients with cirrhosis who underwent contrast-enhanced spectral CT examinations, as well as a control group without major diseases. Iodine concentrations in the liver and aorta were measured on equilibrium phase images to calculate the fECV. The diagnostic performance of fECV for Child-Pugh classification was evaluated using receiver operating characteristic (ROC) curve analysis. The predictive ability of fECV for cirrhosis-related complications was assessed using the Kaplan-Meier time-dependent ROC curves, and Cox proportional hazards regression models.
resultsA total of 116 patients with cirrhosis (mean age, 60.20 ± 12.11 years) and 38 control subjects (mean age, 60.16 ± 8.93 years) were enrolled in this study. The area under the ROC curve (AUC) of fECV for differentiating Child-Pugh classes was 0.852-0.881 (all p < 0.001). The high fECV group (≥38.48%) demonstrated a significantly higher cumulative risk of complications (p < 0.001). fECV showed superior predictive performance for long-term (3-year) complications (AUC = 0.813, p < 0.001). Furthermore, fECV was identified as an independent risk factor for cirrhosis-related complications (Model 1: HR = 1.073, p = 0.004; Model 2: HR = 1.078, p < 0.001).
conclusionfECV is a promising imaging biomarker for liver functional reserve assessment and complication prediction in cirrhosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.